Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ark Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$10,447,022

637 payments

Through program year 2025, Ark Clinical Research is reported as receiving $10,447,022 in research payments, across 637 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,755,972 299
2024 Research $1,838,586 34
2023 Research $2,457,906 138
2022 Research $1,705,717 80
2021 Research $1,617,499 39
2020 Research $816,927 29
2019 Research $254,416 18

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,830,340 36 payments
  2. Regeneron Pharmaceuticals, Inc. $2,163,986 30 payments
  3. Pfizer Inc. $1,915,436 128 payments
  4. AstraZeneca UK Limited $902,030 6 payments
  5. Bavarian Nordic A/S $812,811 100 payments
  6. Boehringer Ingelheim International GmbH $631,956 255 payments
  7. Merck Sharp & Dohme Corporation $333,833 16 payments
  8. Hikma Pharmaceuticals USA $241,454 8 payments
  9. Amgen Inc. $185,423 1 payment
  10. Teva Pharmaceuticals USA, Inc. $128,717 23 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $1,716,946 68 payments
  2. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $1,364,347 10 payments
  3. A Phase I Openlabel Randomized ActiveControlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 Vaccine ARTEMIS C $1,028,659 4 payments
  4. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $902,030 6 payments
  5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $515,134 11 payments
  6. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma $431,412 6 payments
  7. Nct05238025 $393,198 24 payments
  8. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity $391,865 2 payments
  9. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $359,801 46 payments
  10. A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age $333,054 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record